TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma

Svahn,Fredrika; Paulsson,Johan O.; Stenman,Adam; Fotouhi,Omid; Mu,Ninni; Murtha,Timothy D.; Korah,Reju; Carling,Tobias; Bäckdahl,Martin; Wang,Na; Juhlin,C. Christofer; Larsson,Catharina

doi:10.3892/ijmm.2018.3735

TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma

Authors:
- Fredrika Svahn
- Johan O. Paulsson
- Adam Stenman
- Omid Fotouhi
- Ninni Mu
- Timothy D. Murtha
- Reju Korah
- Tobias Carling
- Martin Bäckdahl
- Na Wang
- C. Christofer Juhlin
- Catharina Larsson
View Affiliations

Affiliations: Department of Oncology‑Pathology, Karolinska Institutet, Karolinska University Hospital, Cancer Center Karolinska, SE‑17176 Stockholm, Sweden, Department of Surgery, Yale School of Medicine, Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, CT 06520, USA, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, SE‑17176 Stockholm, Sweden
Published online on: June 20, 2018 https://doi.org/10.3892/ijmm.2018.3735
Pages: 1675-1683

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Telomere maintenance, most commonly achieved by telomerase activation through induction of the telomerase reverse transcriptase (TERT) gene, is required for cell immortalization, a hallmark of cancer. Adrenocortical carcinoma (ACC) is an endocrine tumor for which TERT promoter mutations and telomerase activation have been reported. The present study assessed alterations of the TERT gene locus and telomere length in relation to clinical characteristics in ACC. In total, 38 cases of ACC with known TERT promoter mutational status were included. TERT promoter methylation densities were assessed by pyrosequencing, and TERT copy numbers and telomere length were determined by quantitative polymerase chain reaction analysis, followed by comparison of the mRNA expression of TERT and clinical parameters. The ACC tissue samples showed increased TERT copy numbers, compared with normal adrenal tissue (NAT) samples (P=0.001). Mutually exclusive TERT copy number gains or promoter mutation were present in 70% of the ACC samples. The ACC tissues exhibited higher levels of CpG promoter methylation of all eight CpG sites investigated within the ‑578 to ‑541 bp (Region A), compared with the NATs (P=0.001). High methylation density at this region was associated with metastatic disease and/or relapse, poor survival rates and higher European Network for the Study of Adrenal Tumor stage (P<0.05). The mRNA expression of TERT was inversely correlated with methylation density at ‑162 to ‑100 bp (Region B). Correlation was observed between relative telomere length and the gene expression of TERT. It was concluded that epigenetic alterations of the TERT promoter are frequent and associated with advanced disease and poorer clinical outcome in ACC.

View Figures

View References

1	MacNeil DE, Bensoussan HJ and Autexier C: Telomerase regulation from beginning to the end. Genes (Basel). 7:E642016. View Article : Google Scholar
2	Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA and Fagin JA: Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 98:E1562–E1566. 2013. View Article : Google Scholar : PubMed/NCBI
3	Gisselsson D, Jonson T, Petersén A, Strombeck B, Dal Cin P, Höglund M, Mitelman F, Mertens F and Mandahl N: Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA. 98:12683–12688. 2001. View Article : Google Scholar : PubMed/NCBI
4	Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E and Sturgeon C: Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer. 113:3130–3136. 2008. View Article : Google Scholar : PubMed/NCBI
5	Payabyab EC, Balasubramaniam S, Edgerly M, Velarde M, Merino MJ, Venkatesan AM, Leuva H, Litman T, Bates SE and Fojo T: Adrenocortical cancer: A molecularly complex disease where surgery matters. Clin Cancer Res. 22:4989–5000. 2016. View Article : Google Scholar : PubMed/NCBI
6	Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, et al: Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: A 13-institution study by the US adrenocortical carcinoma group. J Am Coll Surg. 222:480–490. 2016. View Article : Google Scholar : PubMed/NCBI
7	Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, et al: Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab. 100:E493–E502. 2015. View Article : Google Scholar
8	Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, et al: Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 29:723–736. 2016. View Article : Google Scholar : PubMed/NCBI
9	Assie G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, Rene-Corail F, et al: Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 46:607–612. 2014. View Article : Google Scholar : PubMed/NCBI
10	Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Bäckdahl M, Healy JM, Prasad ML, Korah R, Carling T, et al: The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer. 21:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
11	Else T, Giordano TJ and Hammer GD: Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J Clin Endocrinol Metab. 93:1442–1449. 2008. View Article : Google Scholar : PubMed/NCBI
12	Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter mutations in familial and sporadic melanoma. Science. 339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
13	Wang N, Kjellin H, Sofiadis A, Fotouhi O, Juhlin CC, Bäckdahl M, Zedenius J, Xu D, Lehtiö J and Larsson C: Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget. 7:21332–21346. 2016.PubMed/NCBI
14	Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V and Benhattar J: Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 35:1245–1256. 2007. View Article : Google Scholar : PubMed/NCBI
15	DeLellis RA, Lloyd RV, Heitz PU and Eng C: Pathology and genetics of tumours of endocrine organs. Third edition. WHO Classification of Tumours; 8. 2004
16	Moran B, Das S, Smeets D, Peutman G, Klinger R, Fender B, Connor K, Ebert M, Gaiser T, Prehn JH, et al: Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach. Oncotarget. 8:48126–48137. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang N, Xu D, Sofiadis A, Höög A, Vukojević V, Bäckdahl M, Zedenius J and Larsson C: Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J Clin Endocrinol Metab. 99:E1571–E1579. 2014. View Article : Google Scholar : PubMed/NCBI
18	Cawthon RM: Telomere measurement by quantitative PCR. Nucleic Acids Res. 30:e472002. View Article : Google Scholar : PubMed/NCBI
19	Mannelli M, Gelmini S, Arnaldi G, Becherini L, Bemporad D, Crescioli C, Pazzagli M, Mantero F, Serio M and Orlando C: Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. J Clin Endocrinol Metab. 85:468–470. 2000. View Article : Google Scholar : PubMed/NCBI
20	Kjellman M, Kallioniemi OP, Karhu R, Höög A, Farnebo LO, Auer G, Larsson C and Bäckdahl M: Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 56:4219–4223. 1996.PubMed/NCBI
21	Cao Y, Bryan TM and Reddel RR: Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci. 99:1092–1099. 2008. View Article : Google Scholar : PubMed/NCBI
22	Hamidi T, Singh AK and Chen T: Genetic alterations of DNA methylation machinery in human diseases. Epigenomics. 7:247–265. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, Barreau O, de la Villeon B, Faillot S, Hamzaoui N, Neou M, et al: DNA Methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 102:923–932. 2017.
24	Tabori U, Nanda S, Druker H, Lees J and Malkin D: Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res. 67:1415–1418. 2007. View Article : Google Scholar : PubMed/NCBI
25	Hirano Y, Fujita K, Suzuki K, Ushiyama T, Ohtawara Y and Tsuda F: Telomerase activity as an indicator of potentially malignant adrenal tumors. Cancer. 83:772–776. 1998. View Article : Google Scholar : PubMed/NCBI
26	Else T: Telomeres and telomerase in adrenocortical tissue maintenance, carcinogenesis, and aging. J Mol Endocrinol. 43:131–141. 2009. View Article : Google Scholar : PubMed/NCBI